The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}-caprolactone) nanoparticles

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1673-1681

  Xin, Hongliang ^a,b   Sha, Xianyi ^a   Jiang, Xinyi ^a   Chen, Liangcen ^a   Law, Kitki ^a,c   Gu, Jijin ^a   Chen, Yanzuo ^a   Wang, Xiao ^a   Fang, Xiaoling ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Angiopep; Biodistribution; Blood brain barrier; Mechanism; Nanoparticles; Target

Indexed keywords

ALZHEIMER'S DISEASE; ANGIOPEP; APROTININ; BIODISTRIBUTIONS; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN TISSUE; CAPROLACTONE; CAVEOLAE; CONCENTRATION-DEPENDENT; CORONAL SECTIONS; CORTICAL LAYERS; COVALENT BONDING; DRUG DELIVERY SYSTEM; ENERGY DEPENDENT; FLUORESCENT PROBE MOLECULES; IN-VITRO; IN-VIVO; ISOTHIOCYANATES; LATERAL VENTRICLES; NEURODEGENERATIVE DISORDERS; RHODAMINE B; TIME-DEPENDENT; TRANSCYTOSIS;

BLOOD; DRUG DELIVERY; ETHYLENE; GLYCOLS; MAMMALS; MECHANISMS; MOLECULAR BIOLOGY; NANOPARTICLES; NEURODEGENERATIVE DISEASES; POLYETHYLENE GLYCOLS; TARGETS; TISSUE;

BRAIN;

5 (N,N DIMETHYL)AMILORIDE; ANGIOPEP 2; APROTININ; CLATHRIN; COPOLYMER; CYTOCHALASIN D; FILIPIN; GENISTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROGOL; NANOPARTICLE; PEPTIDE; POLY(ETHYLENE GLYCOL) CO POLY(EPSILON CAPROLACTONE); POLYCAPROLACTONE; RHODAMINE B; RHODAMINE B ISOTHIOCYANATE; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN THIRD VENTRICLE; CAVEOLA; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DRUG PENETRATION; DRUG TARGETING; ENDOCYTOSIS; ENERGY; FLUORESCENCE MICROSCOPY; HIPPOCAMPUS; LATERAL BRAIN VENTRICLE; MALE; MEMBRANE MODEL; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; SYNTHESIS; TIME; TRANSCYTOSIS; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; POLYESTERS; POLYETHYLENE GLYCOLS; RHODAMINES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STAINING AND LABELING; STATIC ELECTRICITY; TISSUE DISTRIBUTION;

MUS;

EID: 83355162386     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.018     Document Type: Article

References (40)

1. Pardridge W.M. BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today 2001, 6:381-383.
2. Pardridge W.M. Crossing the blood-brain barrier: are we getting it right?. Drug Discov Today 2001, 6(1):1-2.
3. Pardridge W.M. The lack of BBB research. Drug Discov Today 2002, 7(4):223-226.
4. Grabb P.A., Gilbert M.R. Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg 1995, 82:1053-1058.
5. Pang Z.Q., Lu W., Gao H.L., Hu K.L., Chen J., Zhang C.L., et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008, 128:120-127.
6. Ulbrich K., Knobloch T., Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 2011, 19(2):125-132.
7. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007, 27:909-918.
8. Fillebeen C., Descamps L., Dehouck M.P. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999, 274(11):7011-7017.
9. Demeule M., Poirier J., Jodoin J., Bertrand Y., Desrosiers R.R., Dagenais C., et al. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J Neurochem 2002, 83:924-933.
10. Pan W., Kastin A.J., Zankel T.C., van Kerkhof P., Terasaki T., Bu G., et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci 2004, 117:5071-5078.
11. Demeule M., Régina A., Ché C., Poirier J., Nguyen T., Gabathuler R., et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008, 324(3):1064-1072.
12. Demeule M., Currie J.C., Bertrand Y., Ché C., Nguyen T., Régina A., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 2008, 106(4):1534-1544.
13. Regina A., Demeule M., Ché C., Lavallee I., Poirier J., Gabathuler R., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008, 155:185-197.
14. Maletinska L., Blakely E.A., Bjornstad K.A. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low density lipoprotein receptor-related protein. Cancer Res 2000, 60:2300-2303.
15. Yamamoto M., Ikeda K., Oshshima K., Tsugo H., Kimura H., Tomonaga M., et al. Increased expression of low density lipoprotein receptor-related protein/α2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 1997, 57:2799-2805.
16. Bu G., Maksymovitch E.A., Geuze H., Schwartz A.L. Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J Biol Chem 1994, 269:29874-29882.
17. Xin H.L., Jiang X.Y., Gu J.J., Sha X.Y., Chen L.C., Law k, et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}-caprolactone) nanoparticles as dual-targeted drug delivery system for brain glioma. Biomaterials 2011, 32(18):4293-4305.
18. Zhu Z.S., Li Y., Li X.L., Li R.T., Jia Z.J., Liu B.R., et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(e{open}-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 2010, 142:438-446.
19. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm Res 2002, 19:1137-1143.
20. Lu W., Wan J., She Z.J., Jiang X.G. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007, 118:38-53.
21. Ke W.L., Shao K., Huang R.Q., Han L., Liu Y., Li J.F., et al. Gene delivery targeted to brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009, 30(36):6976-6985.
22. Xie Y., Ye L.Y., Zhang X.B., Hou X.P., Lou J.N. Establishment of an in vitro model of Brain-blood barrier. Beijing Da Xue Xue Bao 2004, 36(4):435-438.
23. Hu K.L., Li J.W., Shen Y.H., Lu W., Gao X.L., Zhang Q.Z., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations delivery. J Control Release 2009, 134:55-61.
24. Persidsky Y., Ramirez S.H., Haorah J., Kanmogne G.D. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006, 1:223-236.
25. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
26. Brightman M.W., Kadota Y. Nonpermeable and permeable vessels of the brain. NIDA Res Monogr 1992, 120:87-107.
27. Petty M.A., Lo E.H. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 2002, 68:311-323.
28. Weiss N., Miller F., Cazaubon S., Couraud P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009, 1788:842-857.
29. Tian W., Ying X., Du J., Guo J., Men Y., Zhang Y., et al. Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur J Pharm Sci 2010, 41(2):232-243.
30. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141:183-192.
31. Liu J., Shapiro J.I. Endocytosis and signal transduction: basic science update. Biol Res Nurs 2003, 5:117-128.
32. Chang J., Jallouli Y., Kroubi M., Yuan X.B., Feng W., Kang C.S., et al. Characterization of endocytosis of transferring-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009, 379:285-292.
33. Aoki T., Nomura R., Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 1999, 253:629-636.
34. Liu P., Anderson R.G. Spatial organization of EGF receptor transmodulation by PDGF. Biochem Biophys Res Commun 1999, 26:695-700.
35. Roger E., Lagarce F., Garcion E., Benoit J.P. Lipid nanocarriers improve paclitaxel transport through human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 2009, 140:174-181.
36. Tahara K., Sakai T., Yamamoto H., Takeuchi H., Hirashima N., Kawashima Y., et al. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm 2009, 382:198-204.
37. Abu Lila A.S., Kizuki S., Doi Y., Suzuki T., Ishida T., Kiwada H., et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009, 137:8-14.
38. Xu Z.H., Chen L.L., Gu W.W., Gao Y., Lin L.P., Zhang Z.W., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226-232.
39. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparicles. J Control Release 2009, 135:259-267.
40. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.